1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Bond Avillion 2 Development LP: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis M1095 (Sonelokimab), Placebo, Secukinumab - Psoriasis | Phase 2 | Completed | Bond Avillion 2 Development LP | 313 | 2018-07-31 | 2021-08-03 |
Psoriasis (1)
secukinumab (1) · sonelokimab (1)
Bulgaria (1) · Canada (1) · Czechia (1) · Germany (1) · Hungary (1) · Poland (1) · United States (1)
Dr. Kim Papp (1)